0 16 CholecystokininB CholecystokininB NNP 17 25 receptor receptor NN 26 30 from from IN 31 36 human human JJ 37 43 Jurkat Jurkat NNP 44 57 lymphoblastic lymphoblastic JJ 58 59 T t NN 60 65 cells cell NNS 66 68 is be VBZ 69 77 involved involve VBN 78 80 in in IN 81 90 activator activator NN 91 111 protein-1-responsive protein-1-responsive JJ 112 116 gene gene NN 117 127 activation activation NN 127 128 . . . 130 133 The the DT 134 137 aim aim NN 138 140 of of IN 141 145 this this DT 146 151 study study NN 152 155 was be VBD 156 158 to to TO 159 166 analyze analyze VB 167 170 the the DT 171 175 role role NN 176 178 of of IN 179 194 cholecystokinin cholecystokinin NN 195 196 ( ( ( 196 203 CCK(B)) cck(b)) NN 204 212 receptor receptor NN 213 215 in in IN 216 221 human human JJ 222 235 lymphoblastic lymphoblastic JJ 236 242 Jurkat Jurkat NNP 243 244 T t NN 245 250 cells cell NNS 250 251 . . . 252 254 We we PRP 255 267 investigated investigate VBD 268 271 the the DT 272 279 trophic trophic JJ 280 286 effect effect NN 287 296 resulting result VBG 297 301 from from IN 302 312 activation activation NN 313 315 of of IN 316 320 such such JJ 321 322 a a DT 323 331 receptor receptor NN 332 334 by by IN 335 340 using use VBG 341 344 the the DT 345 353 reporter reporter NN 354 358 gene gene NN 359 367 strategy strategy NN 367 368 . . . 369 372 For for IN 373 377 this this DT 378 385 purpose purpose NN 385 386 , , , 387 389 we we PRP 390 401 transiently transiently RB 402 413 transfected transfecte VBD 414 420 Jurkat Jurkat NNP 421 422 T t NN 423 428 cells cell NNS 429 433 with with IN 434 437 the the DT 438 446 reporter reporter NN 447 454 plasmid plasmid NN 455 470 p[(TRE)3-tk-Luc p[(tre)3-tk-luc NN 470 471 ] ] ) 472 475 and and CC 476 481 found find VBD 482 486 that that IN 487 492 CCK-8 cck-8 NN 493 496 was be VBD 497 501 able able JJ 502 504 to to TO 505 521 dose-dependently dose-dependently RB 522 528 induce induce VB 529 539 luciferase luciferase NN 540 550 expression expression NN 551 558 related related JJ 559 561 to to TO 562 571 activator activator NN 572 581 protein-1 protein-1 NN 582 583 ( ( ( 583 587 AP-1 ap-1 NN 587 588 ) ) ) 589 599 activation activation NN 600 604 with with IN 605 606 a a DT 607 614 maximal maximal JJ 615 623 response response NN 624 633 identical identical JJ 634 636 to to TO 637 641 that that DT 642 650 obtained obtain VBN 651 655 with with IN 656 665 compounds compound NNS 666 671 known know VBN 672 674 to to TO 675 683 activate activate VB 684 688 AP-1 AP-1 NNP 689 696 complex complex NN 697 698 ( ( ( 698 712 quantitatively quantitatively RB 712 713 , , , 714 717 the the DT 718 722 same same JJ 723 728 level level NN 729 731 of of IN 732 741 induction induction NN 742 745 was be VBD 746 754 obtained obtain VBN 755 759 with with IN 760 761 1 1 CD 762 764 nM nM NNP 765 801 12-O-tetradecanoylphorbol-13-acetate 12-O-tetradecanoylphorbol-13-acetate NNP 801 802 , , , 803 806 100 100 CD 807 813 microM microm NN 814 828 diacylglycerol diacylglycerol NN 828 829 , , , 830 832 or or CC 833 834 4 4 CD 835 837 nM nm NN 838 847 epidermal epidermal JJ 848 854 growth growth NN 855 861 factor factor NN 861 862 ) ) ) 862 863 . . . 864 867 The the DT 868 879 involvement involvement NN 880 882 of of IN 883 886 the the DT 887 893 CCK(B) cck(b) NN 894 902 receptor receptor NN 903 905 in in IN 906 910 such such JJ 911 912 a a DT 913 924 stimulation stimulation NN 925 928 was be VBD 929 941 demonstrated demonstrate VBN 942 944 by by IN 945 948 the the DT 949 959 inhibiting inhibit VBG 960 966 effect effect NN 967 969 of of IN 970 973 the the DT 974 983 selective selective JJ 984 990 CCK(B) cck(b) NN 991 999 receptor receptor NN 1000 1010 antagonist antagonist NN 1011 1021 PD-135,158 pd-135,158 NN 1021 1022 . . . 1023 1027 This this DT 1028 1034 effect effect NN 1035 1038 was be VBD 1039 1048 confirmed confirm VBN 1049 1051 in in IN 1052 1057 COS-7 cos-7 NN 1058 1063 cells cell NNS 1064 1075 transfected transfecte VBN 1076 1080 with with IN 1081 1084 the the DT 1085 1089 cDNA cdna NN 1090 1092 of of IN 1093 1099 CCK(B) cck(b) NN 1100 1108 receptor receptor NN 1109 1115 cloned clone VBN 1116 1120 from from IN 1121 1127 Jurkat Jurkat NNP 1128 1129 T t NN 1130 1135 cells cell NNS 1135 1136 . . . 1137 1139 To to TO 1140 1146 better well RBR 1147 1157 understand understand VB 1158 1161 the the DT 1162 1176 AP-1-dependent ap-1-dependent JJ 1177 1187 luciferase luciferase NN 1188 1198 expression expression NN 1199 1201 in in IN 1202 1208 Jurkat Jurkat NNP 1209 1210 T t NN 1211 1216 cells cell NNS 1216 1217 , , , 1218 1220 we we PRP 1221 1227 tested test VBD 1228 1231 two two CD 1232 1240 specific specific JJ 1241 1251 inhibitors inhibitor NNS 1252 1254 of of IN 1255 1271 serine/threonine serine/threonine NN 1272 1286 phosphatases-1 phosphatases-1 NN 1287 1290 and and CC 1291 1294 -2A -2a NN 1294 1295 : : : 1296 1303 okadaic okadaic JJ 1304 1308 acid acid NN 1309 1312 and and CC 1313 1322 calyculin calyculin NN 1323 1324 A a NN 1324 1325 . . . 1326 1331 These these DT 1332 1341 compounds compound NNS 1342 1350 strongly strongly RB 1351 1360 increased increase VBD 1361 1364 the the DT 1365 1396 phorbol-12-myristate-13-acetate phorbol-12-myristate-13-acetate NN 1397 1405 response response NN 1405 1406 , , , 1407 1414 whereas whereas IN 1415 1417 we we PRP 1418 1422 have have VBP 1423 1426 not not RB 1427 1435 observed observe VBN 1436 1437 a a DT 1438 1450 contribution contribution NN 1451 1453 of of IN 1454 1465 phosphatase phosphatase NN 1466 1476 inhibitors inhibitor NNS 1477 1479 on on IN 1480 1481 a a DT 1482 1495 CCK-8-induced cck-8-induced JJ 1496 1506 luciferase luciferase NN 1507 1515 activity activity NN 1515 1516 . . . 1517 1519 To to TO 1520 1527 confirm confirm VB 1528 1532 that that IN 1533 1539 CCK(B) cck(b) NN 1540 1549 receptors receptor NNS 1550 1553 are be VBP 1554 1562 involved involve VBN 1563 1565 in in IN 1566 1570 AP-1 ap-1 NN 1571 1579 response response NN 1579 1580 , , , 1581 1583 we we PRP 1584 1596 investigated investigate VBD 1597 1600 the the DT 1601 1606 CCK-8 cck-8 NN 1607 1613 effect effect NN 1614 1616 on on IN 1617 1630 interleukin-2 interleukin-2 NN 1631 1641 expression expression NN 1641 1642 , , , 1643 1644 a a DT 1645 1652 natural natural JJ 1653 1663 endogenous endogenous JJ 1664 1668 gene gene NN 1669 1678 regulated regulate VBN 1679 1681 by by IN 1682 1689 several several JJ 1690 1697 factors factor NNS 1697 1698 , , , 1699 1708 including include VBG 1709 1713 AP-1 ap-1 NN 1713 1714 . . . 1715 1717 In in IN 1718 1724 Jurkat Jurkat NNP 1725 1726 T t NN 1727 1732 cells cell NNS 1733 1742 activated activate VBN 1743 1745 by by IN 1746 1777 phorbol-12-myristate-13-acetate phorbol-12-myristate-13-acetate NN 1778 1781 and and CC 1782 1800 phytohemagglutinin phytohemagglutinin NN 1800 1801 , , , 1802 1807 CCK-8 cck-8 NN 1808 1815 induced induce VBD 1816 1820 IL-2 il-2 NN 1821 1831 expression expression NN 1831 1832 . . . 1833 1837 This this DT 1838 1847 induction induction NN 1848 1851 was be VBD 1852 1861 abolished abolish VBN 1862 1864 by by IN 1865 1875 PD-135,158 pd-135,158 NN 1875 1876 . . . 1877 1880 Our our PRP$ 1881 1888 results result NNS 1889 1897 indicate indicate VBP 1898 1902 that that IN 1903 1908 CCK-8 cck-8 NN 1909 1915 exerts exert VBZ 1916 1917 a a DT 1918 1925 trophic trophic JJ 1926 1932 effect effect NN 1933 1935 in in IN 1936 1942 Jurkat Jurkat NNP 1943 1944 T t NN 1945 1950 cells cell NNS 1951 1958 through through IN 1959 1970 stimulation stimulation NN 1971 1973 of of IN 1974 1980 CCK(B) cck(b) NN 1981 1990 receptors receptor NNS 1991 1993 by by IN 1994 2004 modulation modulation NN 2005 2007 of of IN 2008 2018 expression expression NN 2019 2021 of of IN 2022 2036 AP-1-regulated ap-1-regulated JJ 2037 2042 genes gene NNS 2042 2043 . . .